Meredith M Howley1, Eleni A Papadopoulos2, Carla M Van Bennekom3, Alissa R Van Zutphen4, Suzan L Carmichael5, JeanPierre W Munsie6, Michele L Herdt4, Marilyn L Browne7. 1. Birth Defects Research Section, New York State Department of Health, Albany, NY. Electronic address: meredith.howley@health.ny.gov. 2. Birth Defects Research Section, New York State Department of Health, Albany, NY. 3. Slone Epidemiology Center at Boston University, Boston, Mass. 4. Birth Defects Registry, New York State Department of Health, Albany, NY; Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, NY. 5. Division of Neonatal and Developmental Medicine, Department of Pediatrics, and Division of Maternal-Fetal Medicine and Obstetrics, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, Calif. 6. Birth Defects Registry, New York State Department of Health, Albany, NY. 7. Birth Defects Research Section, New York State Department of Health, Albany, NY; Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, NY.
Abstract
BACKGROUND: Evidence regarding associations between maternal asthma medication use and birth defects is mixed. OBJECTIVE: Estimate associations between asthma medciation use and 52 birth defects using National Birth Defects Prevention Study data from 1997 to 2011. METHODS: We compared self-reported maternal asthma medication use for 28,481 birth defect cases and 10,894 nonmalformed controls. We calculated adjusted odds ratios (95% CIs) to estimate the risk of birth defects associated with early pregnancy asthma medication use (the month before through the third month of pregnancy), controlling for maternal age, race/ethnicity, body mass index, smoking, folic acid-containing supplement use, and parity. We calculated risks by medication groupings: bronchodilators, anti-inflammatories, and both. RESULTS: Overall, 1304 (5%) case and 449 (4%) control women reported early pregnancy asthma medication use. We observed an association between asthma medication use and longitudinal limb deficiency (1.81; 95% CI, 1.27-2.58). Early pregnancy bronchodilator-only use was associated with cleft palate (1.50; 95% CI, 1.11-2.02), cleft lip (1.58; 95% CI, 1.12-2.23), longitudinal limb deficiency (2.35; 95% CI, 1.55-3.54), and truncus arteriosus (2.48; 95% CI, 1.13-5.42). Although early pregnancy anti-inflammatory-only use was not associated with the birth defects studied, use of both medications was associated with biliary atresia (3.60; 95% CI, 1.55-8.35) and pulmonary atresia (2.50; 95% CI, 1.09-5.78). CONCLUSIONS: Consistent with previous National Birth Defects Prevention Study analyses, asthma medication use was not associated with most birth defects examined, but we observed modest risks for bronchodilator use and several birth defects. Our findings support maintaining adequate asthma treatment during pregnancy, because early pregnancy asthma exacerbations have been associated with adverse birth outcomes, including birth defects.
BACKGROUND: Evidence regarding associations between maternal asthma medication use and birth defects is mixed. OBJECTIVE: Estimate associations between asthma medciation use and 52 birth defects using National Birth Defects Prevention Study data from 1997 to 2011. METHODS: We compared self-reported maternal asthma medication use for 28,481 birth defect cases and 10,894 nonmalformed controls. We calculated adjusted odds ratios (95% CIs) to estimate the risk of birth defects associated with early pregnancy asthma medication use (the month before through the third month of pregnancy), controlling for maternal age, race/ethnicity, body mass index, smoking, folic acid-containing supplement use, and parity. We calculated risks by medication groupings: bronchodilators, anti-inflammatories, and both. RESULTS: Overall, 1304 (5%) case and 449 (4%) control women reported early pregnancy asthma medication use. We observed an association between asthma medication use and longitudinal limb deficiency (1.81; 95% CI, 1.27-2.58). Early pregnancy bronchodilator-only use was associated with cleft palate (1.50; 95% CI, 1.11-2.02), cleft lip (1.58; 95% CI, 1.12-2.23), longitudinal limb deficiency (2.35; 95% CI, 1.55-3.54), and truncus arteriosus (2.48; 95% CI, 1.13-5.42). Although early pregnancy anti-inflammatory-only use was not associated with the birth defects studied, use of both medications was associated with biliary atresia (3.60; 95% CI, 1.55-8.35) and pulmonary atresia (2.50; 95% CI, 1.09-5.78). CONCLUSIONS: Consistent with previous National Birth Defects Prevention Study analyses, asthma medication use was not associated with most birth defects examined, but we observed modest risks for bronchodilator use and several birth defects. Our findings support maintaining adequate asthma treatment during pregnancy, because early pregnancy asthma exacerbations have been associated with adverse birth outcomes, including birth defects.
Authors: Helen L Kwon; Elizabeth W Triche; Kathleen Belanger; Michael B Bracken Journal: Immunol Allergy Clin North Am Date: 2006-02 Impact factor: 3.479
Authors: Sonja A Rasmussen; Richard S Olney; Lewis B Holmes; Angela E Lin; Kim M Keppler-Noreuil; Cynthia A Moore Journal: Birth Defects Res A Clin Mol Teratol Date: 2003-03
Authors: Ester Garne; Anne Vinkel Hansen; Joan Morris; Louise Zaupper; Marie-Claude Addor; Ingeborg Barisic; Miriam Gatt; Nathalie Lelong; Kari Klungsøyr; Mary O'Mahony; Vera Nelen; Amanda J Neville; Anna Pierini; David Tucker; Hermien de Walle; Awi Wiesel; Maria Loane; Helen Dolk Journal: J Allergy Clin Immunol Date: 2015-07-26 Impact factor: 10.793
Authors: Shao Lin; Jean Pierre W Munsie; Michele L Herdt-Losavio; Erin Bell; Charlotte Druschel; Paul A Romitti; Richard Olney Journal: Am J Epidemiol Date: 2008-04-23 Impact factor: 4.897
Authors: Meredith M Howley; Martha M Werler; Sarah C Fisher; Alissa R Van Zutphen; Suzan L Carmichael; Cheryl S Broussard; Dominique Heinke; Elizabeth C Ailes; Shannon M Pruitt; Jennita Reefhuis; Allen A Mitchell; Marilyn L Browne Journal: Birth Defects Res Date: 2021-07-23 Impact factor: 2.661